Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE versus WYAMYCIN S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE versus WYAMYCIN S.
ILOSONE vs WYAMYCIN S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
WYAMYCIN S (tetracycline) inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
WYAMYCIN S (clarithromycin/sulfamethoxazole) is a fixed-dose combination. Adult: 1 tablet (500 mg clarithromycin/800 mg sulfamethoxazole) orally every 12 hours for 7-14 days.
None Documented
None Documented
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
2-3 hours in normal renal function; prolonged to 24-48 hours in end-stage renal disease.
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Renal (90-95% unchanged via glomerular filtration) and biliary (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic